...
首页> 外文期刊>Journal of vascular surgery >Update on intervention versus medical therapy for atherosclerotic renal artery stenosis
【24h】

Update on intervention versus medical therapy for atherosclerotic renal artery stenosis

机译:动脉粥样硬化性肾动脉狭窄的介入治疗与药物治疗的最新进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Atherosclerotic renal artery stenosis is known to be one of the most common causes of secondary hypertension, and early nonrandomized studies suggested that renal artery stenting (RASt) improved outcomes. The vascular community embraced this less invasive treatment alternative to surgery, and RASt increased in popularity during the late 1990s. However, recent randomized studies have failed to show a benefit regarding blood pressure or renal function when RASt was compared with best medical therapy, creating significant concerns about procedural efficacy. In the wake of these randomized trial results, hypertension and renal disease experts along with vascular interventional specialists now struggle with how to best manage atherosclerotic renal artery stenosis. This review objectively analyzes the current literature and highlights each trial's design weaknesses and strengths. We have provided our recommendations for contemporary treatment guidelines based on our interpretation of the available empirical data.
机译:已知动脉粥样硬化性肾动脉狭窄是继发性高血压的最常见原因之一,早期的非随机研究表明,肾动脉支架置入术(RASt)可改善结局。脉管界接受了这种微创治疗替代手术的方法,在1990年代后期,RASt的受欢迎程度有所提高。然而,当将RASt与最佳药物治疗进行比较时,最近的随机研究未能显示出在血压或肾功能方面的益处,从而引起了对程序功效的重大担忧。在获得这些随机试验结果之后,高血压和肾脏疾病专家以及血管介入专家现在都在努力如何最好地处理动脉粥样硬化性肾动脉狭窄。这篇综述客观地分析了目前的文献,并重点介绍了每个试验的设计弱点和优点。我们根据对现有经验数据的解释为当代治疗指南提供了建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号